- Home
- GHY vs UPB Comparison
GHY vs UPB Comparison
Compare GHY & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHY
- UPB
- Stock Information
- Founded
- GHY 2012
- UPB 2021
- Country
- GHY United States
- UPB United States
- Employees
- GHY N/A
- UPB N/A
- Industry
- GHY Trusts Except Educational Religious and Charitable
- UPB
- Sector
- GHY Finance
- UPB
- Exchange
- GHY Nasdaq
- UPB NYSE
- Market Cap
- GHY 528.3M
- UPB 549.4M
- IPO Year
- GHY N/A
- UPB 2024
- Fundamental
- Price
- GHY $13.12
- UPB $9.81
- Analyst Decision
- GHY
- UPB Strong Buy
- Analyst Count
- GHY 0
- UPB 4
- Target Price
- GHY N/A
- UPB $56.50
- AVG Volume (30 Days)
- GHY 184.8K
- UPB 249.8K
- Earning Date
- GHY 01-01-0001
- UPB 02-14-2025
- Dividend Yield
- GHY 10.58%
- UPB N/A
- EPS Growth
- GHY N/A
- UPB N/A
- EPS
- GHY N/A
- UPB N/A
- Revenue
- GHY N/A
- UPB $2,207,000.00
- Revenue This Year
- GHY N/A
- UPB N/A
- Revenue Next Year
- GHY N/A
- UPB N/A
- P/E Ratio
- GHY N/A
- UPB N/A
- Revenue Growth
- GHY N/A
- UPB 82.10
- 52 Week Low
- GHY $10.24
- UPB $8.36
- 52 Week High
- GHY $11.92
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- GHY 55.61
- UPB N/A
- Support Level
- GHY $12.77
- UPB N/A
- Resistance Level
- GHY $13.45
- UPB N/A
- Average True Range (ATR)
- GHY 0.21
- UPB 0.00
- MACD
- GHY 0.01
- UPB 0.00
- Stochastic Oscillator
- GHY 53.33
- UPB 0.00
About GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.